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Abstract 
Large cell neuroendocrine carcinoma (LCNEC) of the lung is a highly aggressive tumor 
without an established standard treatment. On the other hand, the Hedgehog (Hh) signal, 
which is critical in embryogenesis, is known to play important roles in maintaining a 
malignant phenotype in various cancers. The present study explored the possibility of 
targeting the Hh signal in the treatment of LCNEC by suppressing the Hh downstream 
molecules, Smo and Gli1/2, in 3 human LCNEC cell lines. A Smo inhibitor, BMS-833923, 
and a Gli inhibitor, GANT61, downregulated Gli1 and 2, resulting in the suppression of 
the cell viability of the 3 cell lines assessed using an MTT assay. The downregulation of 
Gli1 and/or Gli2 using siRNA for each gene also led to cell growth inhibition in the 3 cell 
lines. The downregulation of Gli1/2 made the cells more sensitive to cisplatin, resulting 
in increased apoptosis. These findings suggest that the Hh signal pathway might be a 
candidate target for the treatment of LCNEC of the lung. 
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Introduction 
 
The Hedgehog (Hh) signaling pathway is an evolutionarily conserved developmental 
pathway occurring during embryonic development that regulates cell proliferation and 
differentiation (1, 2). In the absence of extracellular Hh ligands, Patched (PTCH) inhibits 
the activity of Smoothened (Smo). Signal transduction is activated when the Hh ligand 
binds to PTCH, relieving its inhibition of Smo, and uninhibited Smo transmits Hh signals 
to the nucleus through the activation of the Gli family of transcription factors. Gli family 
consists of Gli1, Gli2 and Gli3; Gli1 induced Hh-target genes, Gli2 act as an activator or 
a partial repressor, Gli3 mainly act as a repressor (3-7). The Gli1 and Gli2 mRNA levels 
are relevant indicators of Hh pathway activity. Other than during embryonic development, 
the Hh pathway is also activated in mammalian adult tissues, such as the brain and bladder 
(8, 9), where it contributes to the maintenance of tissue homeostasis and facilitates tissue 
repair (10). Moreover, the aberrant augmented activation of Hh signaling has recently 
been shown to play a causative or promoting role in the development and progression of 
various human malignancies, such as lung cancer (11, 12), pleural mesothelioma (13), 
colon cancer (14), melanoma (14) and neuroblastoma (15). 
Large cell neuroendocrine carcinoma (LCNEC) of the lung is a highly aggressive 
4 
 
tumor (16-18). Although patients with early-stage disease are treated surgically, a 
standard therapeutic regimen for advanced-stage disease has not been established, leading 
to a poor therapeutic outcome. Thus, new approaches that target LCNEC are urgently 
needed. The Hh signaling pathway plays an important role in the growth and maintenance 
of a malignant phenotype in small cell lung cancer, which also has neuroendocrine 
features (19, 20). However, the roles of the Hh pathway in LCNEC remain unconfirmed. 
The objective of the present study was to determine whether the Hh pathway is activated 
in LCNEC cells and whether it contributes to cell proliferation. In addition, the potential 
of the Hh pathway as a therapeutic target for LCNEC of the lung was investigated. 
 
Materials and methods 
 
Reagents. The Smo antagonists GDC-0449 (Selleckchem, Houston, USA) and BMS-
833923 (Selleckchem) and the Gli antagonist GANT61 (Wako Pure Chemical Industries, 
Japan) were dissolved in dimethyl sulfoxide (DMSO) in aliquots of 10 mM stock solution 
and stored at -20°C. Cisplatin was purchased from Wako Pure Chemical Industries 
(Japan) and was dissolved in DMSO in aliquots of 10 mM stock solution and stored at 
4°C. 
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Cell lines and cell culture. Three cell lines derived from human LCNEC cells (H460, 
H1299 and H810) and one cell line derived from human lung adenocarcinoma cells 
(A549) were obtained from the American Type Culture Collection (ATCC). H460, H1299 
and A549 were cultured in RPMI 1640 medium (Sigma-Aldrich, St. Louis, USA) 
supplemented with 10% fetal bovine serum (FBS). H810 was cultured in HITES medium 
with 5% FBS that contained DMEM/F12, insulin (5 μg/mL), transferrin (10 μg/mL), 
sodium selenite (30 nM), hydrocortisone (10 nM), β-estradiol (10 nM), and L-glutamine 
(4.5 mM). All the cells were cultured in a 37°C humidified atmosphere containing 5% 
CO2. According to ATCC database, H1299 was confirmed as LCNEC cell line. A 
previous report revealed that H460 and H810 expressed N-CAM and neuroendocrine 
marker such as synaptophysin or chromogranin A (21). Moreover, another report revealed 
that H460 and H810 express high level of neuron-specific enolase (NSE) (22). The cell 
lines of H460, H1299 and H810 were used in several researches as LCNEC (23-25). We 
used A549 in this research as the most adequate positive cellular model of Hh pathway in 
lung cancer. A549 cells have higher level of expression of Hh pathway components than 
other lung cancer cell lines such as A427, NER51 or INER37 (26). Furthermore, 
inhibiting Hh pathway revealed anti-tumor effect on A549 in some previous reports (15, 
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27). 
 
Evaluation of cell viability. Cell viability was determined using the MTT dye reduction 
method. A total of 5,000 cells/well were seeded in 96-well culture plates. The cells were 
treated with various concentrations of GDC-0449, BMS-833923 or GANT61 for 48 h. To 
each well, 15 μL of dye solution (cat. no. G402A; Promega, Madison, USA) was added, 
and the cells were further incubated at 37°C for 4 h, followed by the addition of 100 μL 
of stop solution (cat. no. G4001; Promega) and an additional 1 h of incubation. The 
absorbance at 570 nm of the resulting solution was measured using Infinite 200 PRO 
(FPRO-T; Tecan, Seestrasse, Switzerland). Cell viability was determined by dividing the 
absorbance value of the treated cells by that of the untreated cells. 
 
Small interfering RNA (siRNA) transfection. Predesigned siRNAs targeting human Gli1 
and Gli2 were purchased from Thermo Fisher Scientific (Waltham, USA). As a 
nonspecific control siRNA, scrambled siRNA duplex (Thermo Fisher Scientific) was 
used. Transfections were performed using Lipofectamine RNAiMAX Transfection 
Reagent (Thermo Fisher Scientific) according to the manufacturer’s instructions. Gli1 
and Gli2 were silenced by siRNA for 48 h prior to assay or treatment. 
7 
 
 
Quantitative real-time PCR (qRT-PCR). The expression of mRNA was quantified using 
RT-PCR with the TaqMan Gene Expression Assays, Step One Plus Real-Time PCR 
system, and Step One Software (Thermo Fisher Scientific). After culturing cells at 80% 
confluence in 6-well culture plates, the total RNA was extracted using the RNeasy Mini 
kit (cat. no. 74104; Qiagen, Venlo, Limburg, The Netherlands) and the cDNA was 
immediately synthesized using SuperScript First-Strand Synthesis for RT-PCR (cat. no. 
11904-018; Thermo Fisher Scientific) for RT-PCR according to the manufacturer's 
instructions. The gene expression was quantified relative to the glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) level. TaqMan probes for GAPDH, Smo, Gli1 and 
Gli2 were obtained by ordering from Thermo Fisher Scientific (assay identification 
numbers: Hs02758991_g1, Hs01090242_m1, Hs00171790_m1, Hs01119974_m1). 
 
Apoptosis assay. To determine the caspase 3 and 7 activities, the cells were also seeded 
in 96-well plates in triplicate. At 48 h after treatment with cisplatin, the caspase 3 and 7 
activities were determined using a Caspase-Glo 3/7 kit (cat. no. G8090; Promega), which 
measures caspase 3 and 7 levels in a single assay, according to the manufacturer’s 
instructions. For the fluorescent immunohistochemical evaluation of apoptotic cells, we 
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used the DeadEnd™ Fluorometric TUNEL System (Promega) according to the 
manufacturer’s instructions. A total of 1×105 cells in 1 mL of medium was distributed in 
each well of a Lab-Tek II Chamber Slide (Thermo Fisher Scientific). The cells were 
cultured overnight and treated with 10 μM of cisplatin for 48 h. A small drop of DAPI (1 
µg/mL) in Vectashield anti-fade mounting medium (Vector Labs, Peterborough, UK) was 
placed on each slide, and the specimens were covered with a coverslip. The number of 
fluorescent-positive cells was counted using the cell counter plugin for ImageJ software 
(National Institutes of Health; http://imagej.nih.gov/ij/). 
 
Statistical analyses and ethical considerations. The data were presented as the means ± 
standard errors, and differences between groups were evaluated using the Student t-test. 
Values of P <0.05 (2-tailed) were considered statistically significant. All the experiments 
were conducted in close adherence to institutional regulations. 
 
Results 
 
Expression of Hh pathway signaling components. As markers for Hh signal activation, 
the expressions of Gli1, Gli2 and Smo were evaluated using qRT-PCR. Gli2 and Smo in 
9 
 
H460 cells and Gli1 and Smo in H1299 cells were overexpressed, compared with the level 
in A549 cells. None of the transcription factors were overexpressed in H810 (Fig. 1).  
 
Suppression of Hh pathway signaling and cell viability by Smo or Gli antagonists. A Smo 
antagonist, GDC-0449, failed to exert cytotoxicity in the 3 cell lines, whereas another 
Smo antagonist, BMS-833923, exerted significant cytotoxicity in all 3 cell lines in a dose-
dependent manner, being more pronounced in the H460 and H810 cells than in the H1299 
cells (Fig. 2A). GDC-0449 at a concentration of 10 µM failed to suppress Gli1 expression 
in all 3 cell lines, while it suppressed Gli2 expression solely in H810 cells. In contrast, 
BMS-833923 at a concentration of 5 µM (this dose was determined based on the 
cytotoxicity effect shown in Fig. 2A) did suppress Gli1 expression in all 3 cell lines and 
Gli2 expression in the H460 and H810 cell lines (Fig. 2B). A Gli antagonist, GANT61, 
failed to show significant cytotoxicity in all 3 cell lines, except for within a high dose 
range of 50 to 100 µM (Fig. 2A). When administered at a dose as high as 50 µM, this 
agent suppressed Gli1 expression in H460 and H810 cells, whereas it suppressed Gli2 
expression solely in the H810 cells (Fig. 2B). 
 
Cytotoxicity of silencing Gli using siRNA. The treatment of each cell line with siRNA for 
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Gli1 and Gli2 successfully downregulated the expressions of Gli1 and Gli2, respectively. 
A combination of both siRNAs also successfully downregulated both factors in all 3 cell 
lines (Fig. 3).  
The downregulation of Gli1 and Gli2 equally and significantly suppressed cell 
proliferation in all 3 cell lines. Although the combination of Gli1 and Gli2 downregulation 
significantly suppressed cell growth, no additive effect was observed by the combination, 
compared with the downregulation of a single gene (Fig. 4). 
 
Cisplatin sensitivity and downregulation of Gli expression. The MTT assay demonstrated 
that the downregulation of Gli1, Gli2, and a combination of Gli1 and Gli2 significantly 
enhanced the sensitivity to cisplatin in all 3 cell lines (Fig. 5A). When treated with 
cisplatin, the downregulation of Gli1 and Gli2 induced significantly higher caspase 3 and 
7 activity levels, compared with the control, in all 3 cell lines (Fig. 5B). A TUNEL assay 
also disclosed enhanced apoptosis with cisplatin treatment after Gli downregulation in 
the H460 and H1299 cell lines (Fig. 5C). As repeated TUNEL assays failed to show clear 
TUNEL-positive cells among H810 cells, the results for the H810 cell line are not shown. 
 
Discussion 
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The present study clearly demonstrated a close relationship between the downregulation 
of Gli and cell growth inhibition in 3 human LCNEC cell lines of the lung. That is, the 
Smo inhibitor BMS-833923 and the Gli inhibitor GANT61 significantly suppressed the 
expression of Gli1 and/or Gli2, leading to cell growth inhibition as assessed using an 
MTT assay. The downregulation of Gli1 and/or Gli2 by treatment with siRNA for each 
gene also led to cell growth inhibition. On the other hand, another Smo inhibitor, GDC-
0449, failed to downregulate Gli1 and Gli2, except for Gli2 inhibition in H810 cells, 
leading to non-significant growth inhibition in the 3 cell lines. Although the reason is 
unknown, GDC-0449 was ineffective for inhibiting the cell growth of LCNEC cells 
because it failed to suppress Gli expression. The action mechanisms of GDC-0449 and 
GANT61 were well documented. GDC-0449 binds to the transmembrane domain of Smo 
protein inducing a conformational change in Smo, which results in blocking the signals 
of normal Hh signaling (28), while the action mechanisms of BMS-833923 has not been 
elucidated. On the other hand, GANT61 acts in the nucleus interfering with 
transcriptional factor Gli binding to DNA (29). In contrast, these chemical inhibitors non-
specifically suppressed the expressions of both Gli1 and Gli2, and siRNA for each gene 
specifically suppressed the expression of either Gli1 or Gli2. Interestingly, the 
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suppression of either Gli1 or Gli2 was shown to be sufficient to inhibit cell growth, and 
an additive effect was not observed for the double downregulation of both genes. Whether 
Gli1, Gli2 or their combination is required for Hh-related tumorigenesis remains unclear. 
A previous report demonstrated that Gli1 and Gli2 act as compensation for each other in 
mouse models (30). In some cell lines, inhibiting only Gli1 was not enough to suppressing 
tumor growth because Gli2 can behave like Gli1 in mice (31) and Gli2 also mediates Hh 
signaling pathway (32). Our results also showed that mRNA of Gli2 increased when Gli1 
was suppressed by siRNA and vice versa, implicating those factors act in compensational. 
On the other hand, several studies showed that Gli1, but not Gli2, plays a central role in 
mediating the oncogenic Hh signaling (33-35). Interestingly, the relationship between Hh 
signaling and tumor proliferation was observed even in H810 despite the absence of the 
overexpression of these genes in this cell line, as shown in Fig 1. We showed that Hh 
inhibitors and siRNAs effectively suppressed these baseline expressions of Gli1/2 
together with suppression of cell growth (Fig 2,3,4) in H810. It might be speculated that 
Gli1/2 are essential for cell growth independent of baseline expression. Similar 
phenomena were also observed: Gli1 downregulation in H460 cells led to cell growth 
inhibition despite the fact that these cells did not overexpress Gli1, while Gli2 
downregulation in H1299 cells led to cell growth inhibition despite the fact that these 
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cells do not overexpress Gli2. These facts suggest that both Gli1 and Gli2 independently 
have critical roles in maintaining cell growth ability irrespective of their baseline 
expression levels. In a previous report regarding malignant pleural mesothelioma cells, a 
single treatment with Gli1 or Gli2 siRNA did not produce significant inhibitory effects 
on cell growth, whereas the double downregulation of Gli1 and Gli2 significantly 
inhibited cell proliferation (36). Therefore, the independence of Gli1 and Gli2 might vary 
among tumor types. 
The present research also demonstrated a close relationship between Gli 
downregulation and an increased sensitivity to cisplatin. That is, the downregulation of 
Gli1 and/or Gli2 made the cells more sensitive to cisplatin, possibly through an increase 
in apoptosis as was assessed using caspase 3/7 and TUNEL assays. A previous study also 
revealed that Gli2 knockdown using an antisense oligonucleotide led to enhanced 
chemosensitivity to paclitaxel in prostate cancer (37). Another study showed that 
treatment with GANT61 enhanced the cytotoxicity of cytarabine for acute myeloid 
leukemia (38). As to the underlying mechanism, Sims-Mourtada et al. reported that Gli1 
regulated the ATP-binding cassette transporter family of proteins that is required for drug 
efflux (39). Amable et al. showed that Gli1 plays a role in the cellular accumulation of 
cisplatin through the regulation of multiple transport proteins including octamer-binding 
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protein (OCT)1, OCT2, OCT3, the copper transporter CTR1 and the ATPase copper 
transporter ATP7B (40). On the other hand, cisplatin, in turn, affects the Hh pathway. 
After treatment with cisplatin, DNA repair mechanisms, including nucleotide excision 
repair, mismatch repair and DNA double strand break repair, are upregulated in cancer 
cells to avoid apoptosis. Up-regulated Hh signaling helps the DNA repair mechanisms. 
Suppression of Gli1 by GANT61 down-regulated the genes related to double strand break 
repair by homologous recombination (41) and nucleotide excision repair (42). Therefore, 
there is possibility of synergistic effects of concurrent exposure to cisplatin and Gli 
knockdown. The shortcomings of this research contain the lack of protein expression 
analysis, the lack of confirmation with in vivo experiments and the lack of elucidating 
precise mechanism because of its preliminary nature. Despite these shortages, the present 
research provided evidence supporting Gli as a therapeutic target for the treatment of 
LCNEC of the lung, which is presently an unmet need. 
In conclusion, the present study suggests that Gli activation plays a critical role 
in LCNEC proliferation and drug sensitivity. The inhibition of Gli factors has the potential 
to become an effective approach to the treatment of LCNEC of the lung. 
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Figure 1. Expression of Hh pathway signaling components in LCNEC cell lines. The 
mRNA expression of Hh pathway components was evaluated in 3 human LCNEC cell 
lines and a human adenocarcinoma lung cell line, A549. The mRNA expressions of Smo, 
Gli1, and Gli2 assessed using qRT-PCR in the 3 cell lines were normalized according to 
the expression level in the A549 cells. Compared with the A549 cells, the H460 and 
H1299 cell lines showed a significant overexpression of Smo. The H460 and H1299 cell 
lines also had significant overexpressions of Gli2 and Gli1, respectively. In contrast, H810 
had low expression levels of all 3 genes. The columns and bars represent the means and 
SEs (n = 3), respectively. A single asterisk represents a statistically significant difference 
with P <0.05, while the double asterisks represent a difference with P <0.01. 
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Figure 2. Effects of Smo and Gli inhibitors on LCNEC cell lines. (A) The H460, H1299 
and H810 cell lines were treated with various concentrations of the Smo inhibitors GDC-
0449 and BMS-833923 and the Gli antagonist GANT61 for 48 h. GDC-0449 exhibited 
limited cytotoxicity in all 3 cell lines, whereas BMS-833923 exhibited significant effects 
in all 3 cell lines. GANT61 was not effective enough in suppressing cell viability, because 
a high concentration of the agent up to 100 µM was required to achieve cell viability 
supression. The columns and bars represent the means and SEs (n = 3), respectively. (B) 
The downregulation of Gli1 and Gli2 mRNA by the 3 inhibitors, normalized by the 
mRNA expression levels in the untreated cells, are shown. In this experiment, the 
concentrations of the 3 agents were determined according to the cell viability experiment 
shown in (A) and were 10 µM for GDC-0449 (GDC), 5 µM for BMS-833923 (BMS), 
and 50 µM for GANT61 (GANT). Except for the expression of Gli2 mRNA in the H810 
cells, GDC-0449 did not reduce the mRNA expression levels. BMS-833923 exerted 
significant effects on both Gli1 and Gli2 mRNA, except for the expression of Gli2 mRNA 
in H1299 cells. GANT61 suppressed Gli1 mRNA in the H460 and H810 cell lines and 
Gli2 mRNA in the H810 cell line. The columns and bars represent the means and SEs (n 
= 3), respectively. Ve represents the vehicle alone, without the addition of any agents. A 
single asterisk represents a statistically significant difference with P <0.05, while the 
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double asterisks represent a difference with P <0.01. 
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Figure 3. Silencing Gli factors using siRNA. Each siRNA for Gli1 and Gli2 significantly 
inhibited the expression of the corresponding gene, and their combination significantly 
inhibited both genes in all 3 cell lines. In the columns for the vehicle, the cells were not 
treated with any siRNA, and in the columns for the control, the cells were treated with a 
scrambled siRNA duplex. The columns and bars represent the means and SEs (n = 3), 
respectively. 
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Figure 4. Effects of Gli siRNA on cell growth in LCNEC cell lines. After treatment with 
siRNA for Gli1 and/or Gli2, the cells were seeded on culture plates to examine cell growth. 
Cell viability was determined using the MTT dye reduction method after 24, 48 and 72 h. 
Cell growth, when treated with each siRNA for Gli1 or Gli2, was significantly inhibited 
(P <0.05) at 72 h (asterisks), compared with the control (treatment with scrambled siRNA 
duplex), in all 3 cell lines. However, no additional effect was noted when these 2 siRNAs 
were combined. The dots and bars represent the means and SEs (n = 3), respectively. 
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Figure 5. Cisplatin sensitivity and downregulation of Gli expression. (A) After treatment 
with siRNA, the cells were next treated with various concentrations of cisplatin for 48 h. 
Treatment with siRNA for Gli1, Gli2, or both made all 3 cell lines significantly (P < 0.05, 
as indicated by an asterisk) more sensitive to cisplatin. To verify this phenomenon, 
induction of apoptosis was evaluated using a caspase 3/7 assay (B) and a TUNEL assay 
(C and D). (B) Caspase 3/7 activity was assessed at 48 h post-treatment with cisplatin at 
10 µM, and the activity was significantly enhanced in cells treated with siRNA for Gli1, 
Gli2, or both, whereas apoptosis was not induced in cells treated without cisplatin and 
with siRNA treatment alone. Again, no additive effect was observed for the combination 
of both siRNAs. (C) Apoptotic cells after treatment with cisplatin were evaluated and 
visualized using a TUNEL assay. H460 and H1299 cells treated with Gli1 and/or Gli2 
siRNA were further treated with 10 μM of cisplatin for 48 h. The green and blue 
fluorescence of DAPI shows apoptotic cells and nuclei, respectively. Scale bar, 100 μm.  
(D) The proportions of apoptotic cells were quantified for comparison among the 
treatment groups. The number of TUNEL-positive cells was significantly higher after 
treatment with siRNA for Gli1 and/or Gli2. The asterisks indicate statistically significant 
differences, relative to the control, with a P value <0.05 in A, B and D. The columns and 
bars represent the means and SEs (n = 3), respectively, in B and D. 
29 
 
 
 
 
30 
 
 
  
31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oncology Reports, vol.35, 1148-1154 (2018) 
平成 30年 1月 3日 公表済 
 
